X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

Posted by Geri Gentry on Aug 16th, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) President John Volpone sold 24,576 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president owned 265,305 shares of the company’s stock, valued at $1,177,954.20. This trade represents a 8.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

X4 Pharmaceuticals Stock Down 1.6%

XFOR stock opened at $4.22 on Friday. The company has a market cap of $418.41 million, a P/E ratio of -3.52 and a beta of 0.37. X4 Pharmaceuticals, Inc. has a 52 week low of $2.45 and a 52 week high of $4.83. The company’s 50-day moving average price is $4.05 and its 200 day moving average price is $3.96. The company has a current ratio of 11.30, a quick ratio of 9.98 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The company had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. On average, research analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in XFOR. Pettinga Financial Advisors LLC purchased a new stake in shares of X4 Pharmaceuticals in the second quarter valued at about $47,000. Indivisible Partners acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $40,000. SummitTX Capital L.P. purchased a new position in shares of X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. Squarepoint Ops LLC purchased a new position in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Two Sigma Investments LP acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $47,000. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on XFOR. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Leerink Partners began coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Check Out Our Latest Stock Analysis on X4 Pharmaceuticals

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.